Indian drugmaker Cipla beats Q4 profit estimates on strong US demand
BENGALURU (Reuters) – Cipla, India’s third-largest generic drugmaker by sales, reported fourth-quarter profit above expectations on Friday, driven by strong demand for its products in its key U.S. markets The company reported a 78.5% increase in net profit to 9.39 billion rupees ($112.5 million) for the quarter ended March 31, beating analysts’ estimate of 8.11 …
Indian drugmaker Cipla beats Q4 profit estimates on strong US demand Read More »